- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Taub et al. • 2026 • ASPC The post Prevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease appeared first on Corcept Therapeutics.
DeFronzo et al. • 2026 • Heart in Diabetes The post Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study appeared first on Corcept Therapeutics.
Lorusso et al. • 2026 • ESMO Gyn The post Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10) appeared first on Corcept Therapeutics.
Shahin et al. • 2026 • ESMO Gyn The post Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0) appeared first on Corcept Therapeutics.
DeFronzo et al. • 2026 • ENDO The post Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective Studies appeared first on Corcept Therapeutics.
Eilerman et al. • 2026 • ENDO The post Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol <1.2, 1.2–1.8, and >1.8 μg/dL: Results From the MOMENTUM Study appeared first on Corcept Therapeutics.
Umpierrez et al. • 2026 • ADA The post High Prevalence of Endogenous Hypercortisolism in Patients With Type 2 Diabetes and Resistant Hypertension: Results From the MOMENTUM Study appeared first on Corcept Therapeutics.
Sloan et al. • 2026 • ADA The post Effects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAs appeared first on Corcept Therapeutics.
Hamid et al. • 2026 • ASCO The post SYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies appeared first on Corcept Therapeutics.
Borazanci et al. • 2026 • ASCO The post TRIDENT: A Phase 2 Study of Relacorilant Plus Nab-paclitaxel and Gemcitabine in Chemotherapy-naïve Patients With Metastatic Pancreatic Ductal Adenocarcinoma appeared first on Corcept Therapeutics.